Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer.
Radiol Clin North Am
; 56(3): 485-495, 2018 May.
Article
em En
| MEDLINE
| ID: mdl-29622080
ABSTRACT
The treatment strategy in advanced non-small cell lung cancer (NSCLC) has evolved from empirical chemotherapy to a personalized approach based on histology and molecular markers of primary tumors. Targeted therapies are directed at the products of oncogenic driver mutations. Immunotherapy facilitates the recognition of cancer as foreign by the host immune system, stimulates the immune system, and alleviates the inhibition that allows the growth and spread of cancer cells. The authors describes the role of targeted therapy and immunotherapy in the treatment of NSCLC, patterns of disease present on imaging studies, and immune-related adverse events encountered with immunotherapy.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Terapia de Alvo Molecular
/
Imunoterapia
/
Neoplasias Pulmonares
Limite:
Humans
Idioma:
En
Revista:
Radiol Clin North Am
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Estados Unidos